Health Trials

About this trial

This study is designed as an open-label, single-arm, single-center, phase II clinical trial, aiming to evaluate the efficacy and safety of neoadjuvant Tislelizumab combined with Nab-Paclitaxel followed by distal ureterectomy for patients with non-metastatic ureteral cancer (UTC). Patients enrolled will receive 2-3 cycles of Tislelizumab in combination with Nab-Paclitaxel every 3 weeks and then undergo distal ureterectomy (DU). The assessment of efficacy is based on the histology of specimen from DU, and treatment-related adverse events (TRAEs) will be recorded and evaluated according to CTCAE 5.0.

Eligibility criteria

Qualifiers

Males or females aged no less than 18 years old;

Ureteral cancer indicated by ureteroscopic biopsy and imageological examination (including CT, MRI, or PET-CT), without evidences of metastasis in chest CT scan and abdominal CT scan (T1-4N0-2M0).

Histologically confirmed urothelial carcinoma or urothelial carcinoma as the major pathological component >50% in the specimen from ureteroscopic biopsy;

Suitable and planned to receive distal ureterectomy (including distal ureterectomy + partial cystectomy + ipsilateral pelvic lymph node dissection + psoas hitch procedure + ureteral reimplantation into the bladder).

Disqualifiers

Concurrent primary malignancies in other sites are excluded, except for those with a history of other malignancies that have been treated and are currently stable.

Confirmed bilateral upper tract urothelial carcinoma (UTUC).

Presence of urothelial carcinoma in the renal pelvis or bladder is excluded, except for non-muscle-invasive bladder cancer that can be completely resected via transurethral resection of bladder tumor (TURBT).

Received a live attenuated vaccine within 4 weeks before treatment or plan to receive during the study period;

Trial design

Treatments tested in this trial

  • PD-1 inhibitior
  • Nab-paclitaxel
  • distal ureterectomy

Treatment groups

35 Participants
are divided into 1 treatment group

Locations

1
The Second Hospital of Tianjin Medical University300211, TianjinOutside U.S., China

Sponsors and collaborators

Tianjin Medical University Second Hospital

Lead sponsor

Source ClinicalTrials.gov